EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

EB病毒感染与T细胞淋巴瘤的发生

EB病毒(EBV)是一种DNA肿瘤病毒,以往有关EBV致瘤机制的研究主要集中在B淋巴细胞.日前检测发现人类T细胞淋巴瘤也存在EBV感染.近年来研究表明EBV感染可转化T淋巴细胞,EBV可能在T细胞淋巴瘤的发生中起重要作用.观察LMP1在T细胞中的分子生物效应,有助于了解T淋巴细胞中EBV的感染途径、感染方式以及T细胞淋巴瘤的发生机制.     

Epstein-Barr virus and Burkitt lymphoma

In 1964, a new herpesvirus, Epstein-Barr virus (EBV), was discovered in cultured tumor cel s derived from a Burkitt lymphoma (BL) biopsy taken from an African patient. This was a momentous event that r...     

Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda

Burkitt lymphoma, a childhood tumor common in parts of sub-Saharan Africa, has been directly associated with Epstein-Barr virus (EBV) and indirectly with prevalence of malaria. We studied antibodies to both EBV and malaria in children diagnosed with this cancer in Uganda. We performed a case-control study of HIV-seronegative children (相似文献   

EB病毒阳性老年人弥漫大B细胞淋巴瘤研究进展

 在2008版的WHO分类中EB病毒（EBV）阳性老年人弥漫大B细胞淋巴瘤（DLBCL）作为新的类型被单独特别列出。就其发病机制、病理学特征及鉴别诊断、发现DLBCL中的EBV的方法进行讨论,另外还就DLBCL患者中EBV感染状态潜在的预测和预后价值及对这类肿瘤的治疗策略进行讨论。     

Burkitt淋巴瘤临床分析

目的:分析我中心2007年至2013年确诊的34例Burkitt淋巴瘤（BL）的病理、临床特征及12例临床特点和预后关系。方法:回顾分析2007年-2013年我中心确诊的34例BL（占淋巴瘤总数1.43%,B细胞淋巴瘤2.03%）的病理资料及12例接受治疗的患者临床资料,治疗方法为［hyperCVAD（A+B）±R（利妥昔单抗）］±自体造血干细胞移植（allo-HSCT）,观察短期疗效［完全缓解（CR）和部分缓解（PR）］和长期疗效［包括1年和2年总生存率（OS）及无进展生存率（PFS）］,分析预后影响因素。结果:34例患者中男∶女=10∶7,中位年龄23.5岁（3~74岁）,0~14岁29.4%（10/34）,15~22岁23.5%（8/34）,大于22岁47.1%（16/34）。全身各脏器均可发病,主要以浅表淋巴结、脑部及鼻咽部为主。Ki-67指数均大于95%以上;c-myc阳性77%（10/13）。其中12例在我中心接受治疗,Ⅱ期1例（8.4%）,Ⅲ-Ⅳ期11例（91.7%）。诱导治疗:11例（91.7%）采用hyperCVAD（A+B）方案化疗,3疗程后2例达PR,9例（82%）达CR。9例达CR的患者中有1例采用CHOPE方案巩固化疗,1年内复发;5例采用hyperCVAD（A+B）巩固化疗6疗程,1例1年后复发,2年OS及PFS分别为100%、80%。3例采用hyperCVAD（A+B）+利妥昔单抗（R）方案巩固化疗6疗程,2年OS及PFS均为100%,PFS较未用R组高。3例在巩固、维持治疗后序贯allo-HSCT,随访至2年无复发,病情稳定,OS及PFS均为100%。随访2年无复发8例,年龄小于15岁占50%（4/8）,15~22岁占37.5%（3/8）,大于22岁占12.5%（1/8）。结论:BL主要发生在儿童和青少年,男性高于女性,可累及全身各个器官,诊断时临床分期常较高,需要高强度、高频率、足疗程、规律化疗,尤其是儿童及青少年患者。利妥昔单抗和大剂量化疗药物协同使用,序贯自体造血干细胞移植巩固治疗能提高OS率与PFS,但仍需要临床大样本研究。     

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma

Objective:To characterize modified R-CODOX-M/IVAC-based chemotherapy to lower the severe adverse events in Chinese adult patients with sporadic Burkitt lymphoma.Methods:We enrolled a retrospective cohort including 123 adult patients with untreated sporadic Burkitt lymphoma from August 2008 to September 2019 at Sun Yat-sen University Cancer Center. We studied a dose-modified and long-course R-CODOX-M/IVAC regimen utilizing a low dose of 1.0 g/m²/cycle cyclophosphamide, 2 g/m²/cycle methotrexate, 4,500 mg/m²/cycle ifosfamide, and 4.0 g/m²/cycle cytarabine. Forty-nine patients with low risk disease underwent 4–6 cycles of dose-modified R-CODOX-M-based chemotherapy. Seventy-four patients with high risk disease underwent 6–8 cycles of dose-modified alternating R-CODOX-M/IVAC regimens.Results:The objective remission was 87.0%. The event-free survival rate and overall survival at 3 years were 81.2% and 92.1%, respectively. Major grade 3–4 adverse events included leukopenia (91.9%), anemia (58.5%), thrombocytopenia (73.2%), and febrile neutropenia (48.8%). A total of 26.0% and 37.4% of patients received red blood cell and platelet transfusions, respectively. We observed 4 cases (3.3%) of septic shock after chemotherapy. Two treatment-related deaths occurred from severe infection.Conclusions:The modified R-CODOX-M/IVAC chemotherapy regimen was effective for sporadic Burkitt lymphoma in the Chinese population, with a lower toxicity than standard regimens.     

Improving the accuracy in prognosis for Burkitt lymphoma patients

A recent population-based study on 2000 adult patients with Burkitt lymphoma presented a novel score that takes into account age, race and clinical stage to prognosticate survival. The outcome of patients with Burkitt lymphoma has improved in the last decade, likely due to intensive chemotherapy regimens and anti-CD20 monoclonal antibody therapy. There is, however, a lack of improvement in the outcome of patients older than 60 and in black patients. In this article, we discuss the findings of that study as well as the areas of uncertainty and/or disparity in the prognosis of patients with Burkitt lymphoma.     

PI3K-AKT-mTOR信号通路在伯基特淋巴瘤中的活化

目的 探讨PI3K-AKT-mTOR信号通路在伯基特淋巴瘤中的活化情况.方法 收集13例伯基特淋巴瘤患者淋巴瘤组织及14例患者淋巴结反应性增生组织病理切片,采用免疫组织化学方法检测AKT、mTOR、RPS6磷酸化情况.结果 伯基特淋巴瘤组织中p-AKT、p-mTOR、p-RPS6表达率分别为84.6％(11/13)、100.0％(13/13)、100.0％(13/13),反应性淋巴结增生为64.2 ％(9/14)、71.4％(10/14)、78.6 ％(11/14),阳性表达率差异均具有统计学意义(均P＜0.05).结论 PI3K-AKT-mTOR信号通路在伯基特淋巴瘤中存在异常活化.     

介于弥漫大B 细胞淋巴瘤和伯基特淋巴瘤之间的未分类淋巴瘤

目的：分析介于弥漫大B 细胞淋巴瘤和伯基特淋巴瘤之间的未分类的B 细胞淋巴瘤（B-cell lymphoma ,unclassifiable,with features intermediate between DLBCL and Burkitt lymphoma,DLBCL/BL）的临床特点、治疗与预后,增加对该病的认识。方法：收集郑州大学第一附属医院2013年1 月至2014年12月收治的13例DLBCL/BL患者临床病理资料,采用Kaplan-Meier 法进行生存分析,采用Logrank 检验对临床分期、年龄、LDH 水平、IPI 评分、初治化疗方案等进行单因素分析。结果：13例患者中12例存在结外侵犯,13例患者的中位OS为10个月,中位PFS 为6 个月。单因素分析显示IPI 评分、LDH 水平与预后有统计学相关性,行CHOP、CHOP 样与高强度化疗方案患者之间生存差异具有统计学意义（P = 0.054）。 结论：DLBCL/BL恶性程度高,生存期短,结外侵犯多见,对CHOP 及CHOP 样方案治疗反应差,高强度化疗可能改善预后,IPI 评分≥ 3 分及 LDH 升高是其不良预后因素。     

Incidence of Burkitt lymphoma in the United States during 2000 to 2019

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that occurs worldwide. A study of BL in the US National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program during 1973 to 2005 (n = 3043) revealed three age-specific incidence peaks of BL and rates that were rising. We studied BL cases diagnosed in SEER 22 during 2000 to 2019 (n = 11 626) to investigate age-specific BL incidence rates and temporal trends. The age-standardized BL incidence rate was 3.96/million person-years, with a 2.85:1 male-to-female ratio. The BL rate among both Hispanic and White individuals was higher than in Black individuals (4.52, 4.12 vs 3.14). Age-specific BL rates showed peaks during pediatric, adult and elderly years in males and pediatric and elderly peaks in females. Based on 4524 BL cases with HIV status (SEER 13), only one peak in adult males (45 years) was observed. Overall age-standardized BL incidence rates rose 1.2%/year (not significant) up to 2009 then fell significantly by 2.4%/year thereafter. Temporal trends in BL rates during 2000 to 2019 varied with age group as pediatric BL rates rose 1.1%/year, while elderly BL rates fell 1.7%/year and adult BL rates rose 3.4%/year until 2007 before falling 3.1%/year thereafter. Overall survival from BL was 64% at 2 years, being highest in pediatric patients and lowest in Black and elderly individuals vs other subgroups. Survival improved by 20% between 2000 and 2019. Our data suggest that BL age-specific incidence rates are multimodal and that overall BL rates rose up to 2009 and then fell, suggesting changes in etiological factors or diagnosis.